Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0237 | 1 | 1 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.014 | 0.2852 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0237 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0233 | 0.9706 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0237 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.014 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0233 | 0.9706 | 0.9706 |
Mycobacterium ulcerans | hypothetical protein | 0.014 | 0.2852 | 0.5 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.0237 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.014 | 0.2852 | 0.5 |
Onchocerca volvulus | 0.0237 | 1 | 0.5 | |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0233 | 0.9706 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0237 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0233 | 0.9706 | 0.9604 |
Schistosoma mansoni | 6-phosphofructokinase | 0.0237 | 1 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.014 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0237 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0233 | 0.9706 | 0.9706 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | > 125 uM | Inhibition of human recombinant LSD1 (157 to 852 aa) expressed in Escherichia coli BL21(DE) using H3K4me2 as substrate by fluorescence assay | ChEMBL. | 24131029 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.